The clinicopathological and prognostic significance of autonomic nerves in salivary duct carcinoma-Reference-Cited by-同舟云学术

The clinicopathological and prognostic significance of autonomic nerves in salivary duct carcinoma

Published:2024-07-23 Issue: Volume: Page:
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Kajiwara Manami,Takahashi Hideaki,Nakaguro Masato^ORCID,Kawakita Daisuke^ORCID,Hirai Hideaki,Utsumi Yoshitaka,Urano Makoto,Sato Yukiko,Tsukahara Kiyoaki,Kano Satoshi,Okami Kenji,Ozawa Hiroyuki,Yamazaki Keisuke,Okada Takuro,Shimizu Akira,Hanyu Kenji,Sakai Akihiro,Yamauchi Mayu,Sekimizu Mariko,Hanazawa Toyoyuki,Saito Yuki,Ueki Yushi,Honma Yoshitaka,Arai Tomoyuki,Iwaki Sho,Yamamura Koji,Imanishi Yorihisa,Sato Yuichiro,Tada Yuichiro^ORCID,Nagao Toshitaka^ORCID,

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00428-024-03873-x.pdf

Reference33 articles.

1. Chiosea S, Agaimy A, Nagao T et al (2022) Salivary duct carcinoma. In: WHO Classification of Head and Neck Tumours (WHO Classification of tumours series, 5th ed.; vol.9). https://tumourclassification.iarc.who.int/chapters/52. Accessed 5 February 2024

2. Nakaguro M, Tada Y, Faquin WC et al (2020) Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment. Cancer Cytopathol 128:693–703. https://doi.org/10.1002/cncy.22288

3. Kawakita D, Nagao T, Takahashi H et al (2022) Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. Ther Adv Med Oncol 14. https://doi.org/10.1177/17588359221119538

4. Even C, Delord J-P, Price KA et al (2022) Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. Eur J Cancer 171:259–268. https://doi.org/10.1016/j.ejca.2022.05.007

5. Vos JL, Burman B, Jain S et al (2023) Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nat Med 29:3077–3089. https://doi.org/10.1038/s41591-023-02518-x